BACKGROUND AND PURPOSE: The NO redox sibling nitroxyl (HNO) elicits soluble guanylyl cyclase (sGC)-dependent vasodilatation. HNO has high reactivity with thiols, which is attributed with HNO-enhanced left ventricular (LV) function. Here, we tested the hypothesis that the concomitant vasodilatation and inotropic actions induced by a HNO donor, Angeli's salt (sodium trioxodinitrate), were sGC-dependent and sGC-independent respectively. EXPERIMENTAL APPROACH: Haemodynamic responses to Angeli's salt (10 pmol-10 μmol), alone and in the presence of scavengers of HNO (L-cysteine, 4 mM) or of NO [hydroxocobalamin (HXC), 100 μM] or a selective inhibitor of sGC [1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 10 μM], a CGRP receptor antagonist (CGRP8-37 , 0.1 μM) or a blocker of voltage-dependent potassium channels [4-aminopyridine (4-AP), 1 mM] were determined in isolated hearts from male rats. KEY RESULTS: Angeli's salt elicited concomitant, dose-dependent increases in coronary flow and LV systolic and diastolic function. Both L-cysteine and ODQ shifted (but did not abolish) the dose-response curve of each of these effects to the right, implying contributions from HNO and sGC in both the vasodilator and inotropic actions. In contrast, neither HXC, CGRP8-37 nor 4-AP affected these actions. CONCLUSIONS AND IMPLICATIONS: Both vasodilator and inotropic actions of the HNO donor Angeli's salt were mediated in part by sGC-dependent mechanisms, representing the first evidence that sGC contributes to the inotropic and lusitropic action of HNO in the intact heart. Thus, HNO acutely enhances LV contraction and relaxation, while concomitantly unloading the heart, potentially beneficial actions in failing hearts.
BACKGROUND AND PURPOSE: The NO redox sibling nitroxyl (HNO) elicits soluble guanylyl cyclase (sGC)-dependent vasodilatation. HNO has high reactivity with thiols, which is attributed with HNO-enhanced left ventricular (LV) function. Here, we tested the hypothesis that the concomitant vasodilatation and inotropic actions induced by a HNOdonor, Angeli's salt (sodium trioxodinitrate), were sGC-dependent and sGC-independent respectively. EXPERIMENTAL APPROACH: Haemodynamic responses to Angeli's salt (10 pmol-10 μmol), alone and in the presence of scavengers of HNO (L-cysteine, 4 mM) or of NO [hydroxocobalamin (HXC), 100 μM] or a selective inhibitor of sGC [1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 10 μM], a CGRP receptor antagonist (CGRP8-37 , 0.1 μM) or a blocker of voltage-dependent potassium channels [4-aminopyridine (4-AP), 1 mM] were determined in isolated hearts from male rats. KEY RESULTS:Angeli's salt elicited concomitant, dose-dependent increases in coronary flow and LV systolic and diastolic function. Both L-cysteine and ODQ shifted (but did not abolish) the dose-response curve of each of these effects to the right, implying contributions from HNO and sGC in both the vasodilator and inotropic actions. In contrast, neither HXC, CGRP8-37 nor 4-AP affected these actions. CONCLUSIONS AND IMPLICATIONS: Both vasodilator and inotropic actions of the HNOdonorAngeli's salt were mediated in part by sGC-dependent mechanisms, representing the first evidence that sGC contributes to the inotropic and lusitropic action of HNO in the intact heart. Thus, HNO acutely enhances LV contraction and relaxation, while concomitantly unloading the heart, potentially beneficial actions in failing hearts.
Authors: Nazareno Paolocci; Tatsuo Katori; Hunter C Champion; Marcus E St John; Katrina M Miranda; Jon M Fukuto; David A Wink; David A Kass Journal: Proc Natl Acad Sci U S A Date: 2003-04-18 Impact factor: 11.205
Authors: Kathryn H Yuill; Polina Yarova; Barbara K Kemp-Harper; Christopher J Garland; Kim A Dora Journal: Antioxid Redox Signal Date: 2010-10-07 Impact factor: 8.401
Authors: Carlo G Tocchetti; Brian A Stanley; Christopher I Murray; Vidhya Sivakumaran; Sonia Donzelli; Daniele Mancardi; Pasquale Pagliaro; Wei Dong Gao; Jennifer van Eyk; David A Kass; David A Wink; Nazareno Paolocci Journal: Antioxid Redox Signal Date: 2011-03-03 Impact factor: 8.401
Authors: Ali El-Armouche; Azadeh Wahab; Katrin Wittköpper; Thomas Schulze; Felix Böttcher; Lutz Pohlmann; S Bruce King; Jenna F DuMond; Christian Gerloff; Rainer H Böger; Thomas Eschenhagen; Lucie Carrier; Sonia Donzelli Journal: Biochem Biophys Res Commun Date: 2010-10-12 Impact factor: 3.575
Authors: Katrina M Miranda; Ken-ichi Yamada; Michael G Espey; Douglas D Thomas; William DeGraff; James B Mitchell; Murali C Krishna; Carol A Colton; David A Wink Journal: Arch Biochem Biophys Date: 2002-05-15 Impact factor: 4.013
Authors: Maria Ntessalen; Nathan E K Procter; Konstantin Schwarz; Brodie L Loudon; Magdalena Minnion; Bernadette O Fernandez; Vassilios S Vassiliou; David Vauzour; Melanie Madhani; Dumitru Constantin-Teodosiu; John D Horowitz; Martin Feelisch; Dana Dawson; Paul G Crichton; Michael P Frenneaux Journal: Am J Clin Nutr Date: 2020-01-01 Impact factor: 7.045
Authors: Anida Velagic; Jasmin Chendi Li; Cheng Xue Qin; Mandy Li; Minh Deo; Sarah A Marshall; Dovile Anderson; Owen L Woodman; John D Horowitz; Barbara K Kemp-Harper; Rebecca H Ritchie Journal: Br J Pharmacol Date: 2022-04-26 Impact factor: 9.473
Authors: Douglas Cowart; Robert P Venuti; Kim Lynch; Jeffrey T Guptill; Robert J Noveck; Shi Yin Foo Journal: J Clin Pharmacol Date: 2019-01-31 Impact factor: 3.126